Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 11,445 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 11,445 shares of the stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $18.92, for a total value of $216,539.40. Following the completion of the sale, the chief executive officer directly owned 309,892 shares of the company’s stock, valued at approximately $5,863,156.64. The trade was a 3.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Claire Mazumdar also recently made the following trade(s):

• On Wednesday, October 15th, Claire Mazumdar sold 13,289 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.84, for a total transaction of $250,364.76.

Bicara Therapeutics Trading Up 8.7%

Shares of Bicara Therapeutics stock opened at $18.81 on Thursday. The business has a 50-day moving average price of $12.94 and a two-hundred day moving average price of $11.97. Bicara Therapeutics Inc. has a 1-year low of $7.80 and a 1-year high of $28.09. The company has a market cap of $1.03 billion and a P/E ratio of -5.93.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.04. Equities research analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on BCAX shares. Piper Sandler started coverage on shares of Bicara Therapeutics in a research report on Monday, August 18th. They set an “overweight” rating and a $36.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Tuesday. Wedbush restated an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a report on Tuesday, August 12th. Finally, HC Wainwright decreased their price objective on Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a report on Friday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Bicara Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $31.86.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC boosted its position in shares of Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after buying an additional 3,866 shares during the last quarter. Vestal Point Capital LP lifted its stake in Bicara Therapeutics by 80.6% during the 2nd quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock valued at $46,450,000 after acquiring an additional 2,231,025 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Bicara Therapeutics by 2,351.0% in the second quarter. Bank of America Corp DE now owns 451,228 shares of the company’s stock valued at $4,192,000 after purchasing an additional 432,818 shares during the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of Bicara Therapeutics in the second quarter valued at about $149,000. Finally, Jane Street Group LLC purchased a new stake in shares of Bicara Therapeutics in the second quarter valued at about $266,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.